Article

AMO sharpens focus on innovative technology

Author(s):

Mark L. Dlugoss

A sign of an excellent company is one that capitalizes on its strengths, minimizes its weaknesses, takes advantage of its opportunities, and recognizes its threats, according to James V. Mazzo, president and chief executive officer of Advanced Medical Optics (AMO).

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
Related Content
(Image credit: Wilmer Eye Institute/Johns Hopkins Medicine)
June 27th 2025

Wilmer Eye Institute marks 100 years: honoring the past, shaping the future

3 Things You Should Know About the GA Pipeline
June 4th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

Krystal Biotech doses first patient in phase 3 trial IOLITE
June 27th 2025

Krystal Biotech doses first patient in phase 3 trial IOLITE

Patient-Centered Treatment Strategies in the Management of nAMD and DME
May 30th 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

Aldeyra Therapeutics receives Special Protocol Assessment Agreement Letter from FDA for ADX-2191
June 26th 2025

Aldeyra Therapeutics receives Special Protocol Assessment Agreement Letter from FDA for ADX-2191

36-month results from phase 1/2a clinical study of RG6501 released
June 26th 2025

36-month results from phase 1/2a clinical study of RG6501 released

© 2025 MJH Life Sciences

All rights reserved.